Aktiesnakken — September 2013
-
Humax-tf-ADC bliver langt større end vi tror. Det er selvfølgelig stadig high risk. men det henvender sig altså mod de aller største indikationer af solid tumors. Kan genmab komme ind der er det mega gennembrud
-
jeg vil ikke afvise at humax kan blive en milliard værd for genmab, men jeg synes ikke den er det nu
-
så er vi igennem
-
Carnegie er med !
-
carnegie er the guys
-
solsen er også the guy
-
det er pænt af dig at sige....men jeg vil hellere have taget dem i 156
-
BTD på arzerra var meget meget afgørende
-
på den korte/mellemlange bane
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind